Longevity Report · September · Issue 3

GLP-1 Drugs Move Beyond Weight Loss to Kidney and Cancer Outcomes

The most common mistake right now is treating the GLP-1 cancer signal as if it were a kidney-trial result. A viral post from Dr. William Li claims GLP-1 drugs were associated with 30–50% lower colon cancer recurrence, along with signals of fewer metastases across data from 30 million users. That is a social-media claim.

Social-media cancer-recurrence signals are not kidney-trial evidence; peer-reviewed outcome data must be tracked before clinical conclusions.
Article 1 of this issue · 4 more inside
Discover sift.
Subscribe to any topic. AI researches the web and turns the signal into a private weekly magazine.

One issue a week. Free.

sift. reads hundreds of sources so you don't have to, and sends one issue you can actually finish. No daily noise. Unsubscribe anytime.